LOC729103 Inhibitors

Erlotinib and Lapatinib are examples of kinase inhibitors that target the EGFR family of tyrosine kinases, known to play a key role in cell proliferation and survival. Their inhibition can affect downstream proteins that are responsive to EGFR signaling. Crizotinib, a selective ALK inhibitor, and Axitinib, a VEGFR inhibitor, can alter the activity of proteins involved in processes such as cell growth and angiogenesis by suppressing the respective tyrosine kinase activities.

PD 0332991 hydrochloride and Vemurafenib represent inhibitors that target key regulators of cell cycle progression and the MAPK signaling pathway, respectively. The former can influence proteins that are regulated by cyclin-dependent kinases involved in cell cycle control, while the latter can impact proteins that are part of the MAPK pathway often implicated in cell differentiation and proliferation. Temsirolimus and Cobimetinib are inhibitors that act on components of the mTOR and MAPK/ERK pathways. By impeding these pathways, these inhibitors can regulate proteins involved in crucial cellular processes, including growth, proliferation, and response to extracellular signals. ABT-199, a BCL-2 inhibitor, and Olaparib, a PARP inhibitor, represent compounds that can induce cell death or affect DNA repair mechanisms, thereby influencing proteins that are part of apoptotic pathways or DNA damage responses. Bosutinib, which targets Src and Abl kinases, can modulate proteins involved in signal transduction pathways that govern cell adhesion, migration, and proliferation.